HIV-1 envelope glycoprotein gp120-targeting broadly neutralizing antibody VRC07-523LS (VRC07-523LS)

VRC07-523LS is a next-generation human IgG1 monoclonal antibody engineered for exceptional breadth and potency against HIV-1. It specifically targets the CD4-binding site (CD4bs) of the HIV-1 envelope glycoprotein gp120, effectively blocking viral entry into host cells. VRC07-523LS is derived from the parental VRC01 antibody through extensive mutagenesis to improve its potency (about 5- to 8-fold greater neutralization compared to VRC01) and breadth (neutralizes up to 96% of tested HIV-1 strains). The addition of the LS mutation to the Fc region further extends its serum half-life, supporting less frequent dosing in prophylaxis or therapeutic regimens. Clinical trials have demonstrated favorable safety and pharmacokinetics in adults, children, and infants, and ongoing research is evaluating its role in combination antibody strategies for HIV-1 prevention and treatment.

Other names

VRC07-523-LSVRC07–523LSVRC07-523

VRC07-523LS binds with high affinity to the conserved CD4-binding site on the HIV-1 envelope glycoprotein gp120, blocking the interaction with the CD4 receptor on host cells and thereby preventing virus entry and infection. LS mutation (M428L/N434S in the Fc region) extends the antibody half-life by enhancing neonatal Fc receptor (FcRn) binding and recycling.